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background 
 
Available treatments for hepatitis B e antigen (HBeAg)–negative chronic hepatitis B are
associated with poor sustained responses. As a result, nucleoside and nucleotide ana-
logues are typically continued indefinitely, a strategy associated with the risk of resis-
tance and unknown long-term safety implications.
 
methods 
 
We compared the efficacy and safety of peginterferon alfa-2a (180 µg once weekly) plus
placebo, peginterferon alfa-2a plus lamivudine (100 mg daily), and lamivudine alone
in 177, 179, and 181 patients with HBeAg-negative chronic hepatitis B, respectively.
Patients were treated for 48 weeks and followed for an additional 24 weeks.
 
results 
 
After 24 weeks of follow-up, the percentage of patients with normalization of alanine
aminotransferase levels or hepatitis B virus (HBV) DNA levels below 20,000 copies per
milliliter was significantly higher with peginterferon alfa-2a monotherapy (59 percent
and 43 percent, respectively) and peginterferon alfa-2a plus lamivudine (60 percent
and 44 percent) than with lamivudine monotherapy (44 percent, P=0.004 and P=0.003,
respectively; and 29 percent, P=0.007 and P=0.003, respectively). Rates of sustained
suppression of HBV DNA to below 400 copies per milliliter were 19 percent with
peginterferon alfa-2a monotherapy, 20 percent with combination therapy, and 7 percent
with lamivudine alone (P<0.001 for both comparisons with lamivudine alone). Loss of
hepatitis B surface antigen occurred in 12 patients in the peginterferon groups, as com-
pared with 0 patients in the group given lamivudine alone. Adverse events, including py-
rexia, fatigue, myalgia, and headache, were less frequent with lamivudine monotherapy
than with peginterferon alfa-2a monotherapy or combination therapy. 
 
conclusions 
 
Patients with HBeAg-negative chronic hepatitis B had significantly higher rates of re-
sponse, sustained for 24 weeks after the cessation of therapy, with peginterferon alfa-2a
than with lamivudine. The addition of lamivudine to peginterferon alfa-2a did not im-
prove post-therapy response rates.
abstract
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hronic infection with hepatitis b
 
virus (HBV) is a major global health prob-
lem, affecting more than 400 million peo-
ple worldwide.
 
1
 
 Chronic hepatitis B is associated
with serious complications, including liver failure,
cirrhosis, and hepatocellular carcinoma. Hepatitis
B e antigen (HBeAg)–negative chronic hepatitis B
represents a late phase of the infection that is char-
acterized by progressive liver damage
 
2,3
 
 and viral
variants with changes in the precore or core promot-
er region,
 
4,5
 
 which abolish or suppress the expres-
sion of HBeAg. Spontaneous, sustained remissions
are rare in HBeAg-negative chronic hepatitis B,
 
6
 
which has a poor prognosis. HBeAg-negative
chronic hepatitis B occurs throughout the world,
and its prevalence is increasing.
 
4,6
 
HBeAg-negative chronic hepatitis B responds
well to currently available therapies during treat-
ment. However, relapse rates are high after treat-
ment cessation, and the rates of sustained response
are poor.
 
7-10
 
 Current consensus guidelines rec-
ommend the use of interferon alfa or nucleoside
or nucleotide analogues as first-line therapy for
HBeAg-negative chronic hepatitis B.
 
6,11-13
 
 How-
ever, conventional interferon alfa has suboptimal
pharmacokinetics, necessitating an inconvenient
dosing regimen. Lamivudine is associated with
drug resistance, which increases with extended
use.
 
14,15
 
 Studies in patients with chronic hepatitis
B have produced conflicting results regarding the
benefits of combining interferon alfa and lamivu-
dine,
 
16-18
 
 and the role of such combinations in the
treatment of chronic hepatitis B requires further
clarification.
Peginterferon alfa-2a, created by attaching a
large, branched, 40-kD polyethylene glycol mole-
cule to interferon alfa-2a,
 
19
 
 has better pharmaco-
kinetics than conventional interferon alfa.
 
20
 
 This
allows for convenient once-weekly dosing, with ef-
fective serum levels maintained throughout the
dosing interval.
 
20
 
 Peginterferon alfa-2a, like con-
ventional interferon alfa, has a dual immunomod-
ulatory and antiviral mode of action but has yielded
superior clinical outcomes in patients with chronic
hepatitis C
 
21
 
 and patients with HBeAg-positive
chronic hepatitis B.
 
22
 
 The current study was de-
signed to assess the efficacy and safety of three
regimens in patients with HBeAg-negative chronic
hepatitis B: peginterferon alfa-2a monotherapy,
peginterferon alfa-2a plus lamivudine, and lamivu-
dine monotherapy.
 
study design
 
This multicenter, randomized, partially double-
blind study was conducted at 54 sites in 13 countries,
principally in Asia and Europe. Patients were ran-
domly assigned in a 1:1:1 ratio to receive 180 µg of
peginterferon alfa-2a (Pegasys, Roche) once weekly
plus oral placebo once daily, 180 µg of peginter-
feron alfa-2a once weekly plus 100 mg of lamivu-
dine (Epivir-HBV or Zeffix, GlaxoSmithKline) once
daily, or 100 mg of lamivudine once daily. Random-
ization was centralized and stratified according
to geographic region and alanine aminotransfer-
ase levels. The study, which comprised 48 weeks
of treatment followed by 24 weeks of follow-up,
was conducted according to the guidelines of the
Declaration of Helsinki and the principles of Good
Clinical Practice. All patients gave written informed
consent.
The study was designed by the sponsor (Roche)
in collaboration with expert hepatologists. Clinical
data were collected by the Peginterferon Alfa-2a
HBeAg-Negative Chronic Hepatitis B Study Group.
The sponsor held the data and conducted the sta-
tistical analyses; the principal authors had full ac-
cess to the data and were actively involved in the
analysis and interpretation of the data and the draft-
ing of the manuscript. All authors approved the fi-
nal manuscript.
 
patients
 
Adult patients were eligible if they had been nega-
tive for HBeAg and positive for anti-HBe antibody
and hepatitis B surface antigen (HBsAg) for at least
six months, had an HBV DNA level of more than
100,000 copies per milliliter, had a serum alanine
aminotransferase level that was greater than 1 but
less than or equal to 10 times the upper limit of the
normal range, and had had findings on a liver bi-
opsy within the previous 24 months consistent
with the presence of chronic hepatitis B, with evi-
dence of prominent necroinflammatory activity (as
assessed by a local pathologist). Exclusion criteria
included decompensated liver disease, a coexisting
serious medical or psychiatric illness, a neutrophil
count of less than 1500 per cubic millimeter, a plate-
let count of less than 90,000 per cubic millimeter,
a serum creatinine level that was more than 1.5
times the upper limit of the normal range, a history
of alcohol or drug abuse within one year before en-
c methods
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try, treatment for chronic hepatitis B within the pre-
vious six months, and coinfection with hepatitis C
virus (HCV) or hepatitis D virus or human immu-
nodeficiency virus.
 
efficacy measures
 
Efficacy analyses included all randomized patients
who received at least one dose of study medication.
The study had two predetermined primary mea-
sures of efficacy assessed after 24 weeks of follow-
up: the normalization of alanine aminotransferase
levels and the suppression of HBV DNA levels to
below 20,000 copies per milliliter. Alanine amino-
transferase was measured at local laboratories in
accordance with standard procedures. Serum HBV
DNA was measured at one of three central labo-
ratories with the use of the Cobas Amplicor HBV
Monitor Test (Roche Diagnostics).
Secondary efficacy measures assessed after 24
weeks of follow-up included the proportion of
patients with HBsAg loss, HBsAg seroconversion
(defined by the loss of HBsAg and the presence of
anti-HBs antibody), histologic response, and sup-
pression of HBV DNA to below 400 copies per mil-
liliter. A histologic response was defined as a reduc-
tion of at least two points in the modified Histologic
Activity Index score as compared with the pretreat-
ment score. Scores for this index can range from
0 to 24, with inflammation graded from 0 (none) to
18 (severe) and fibrosis graded from 0 (none) to
6 (cirrhosis).
 
23
 
 Biopsy samples were scored by an
independent histopathologist who was unaware of
the timing of the biopsy or the patient’s treatment
assignment. Ranked assessments of necroinflam-
matory activity and fibrosis were also performed
(and scored as improved, unchanged, or worse).
 
safety analysis
 
Measures of safety included adverse events, hema-
tologic measurements, clinical chemical measure-
ments, and vital signs. Adverse events were graded
on a three-point scale (mild, moderate, and severe),
and causality was determined by the investigator.
Safety was assessed at baseline; at weeks 1, 2, 4, 6,
8, and 12 and every six weeks thereafter through-
out treatment; and every four weeks during fol-
low-up. Safety analyses included all randomized
patients who received at least one dose of study med-
ication and who underwent at least one safety as-
sessment after baseline.
 
resistance analysis
 
At the end of treatment (week 48), HBV DNA was
extracted from all available serum samples from
patients in the two lamivudine groups. Mutations
in the YMDD (tyrosine, methionine, aspartate, and
aspartate) motif of the HBV polymerase gene were
identified by means of the INNO-LiPA HBV DR as-
say (Innogenetics).
 
24
 
statistical analysis
 
A sample size of 160 patients per treatment group
provided the study with a statistical power of 80
percent at the 0.025 level of significance to detect
a difference in response rates of 15 percent. The
sample size was increased to 175 patients to allow
for withdrawals. The goals of the study were con-
sidered to have been reached in the event of a sig-
nificant result for either primary efficacy outcome.
Therefore, a significance level of 0.025 was cho-
sen for the two primary efficacy measures to main-
tain the overall significance level at 0.05. For sec-
ondary efficacy measures, the level of significance
was set at 0.05.
The Cochran–Mantel–Haenszel test, stratified
according to geographic region and pretreatment
alanine aminotransferase level, was used to compare
differences in response rates between the treatment
groups. Only if the overall test of the treatment ef-
fect was significant were pairwise comparisons per-
formed. Fisher’s exact test was used when appro-
priate. For each treatment group, response rates
were computed with their corresponding 95 percent
confidence intervals. No interim analyses were per-
formed. Response rates were calculated for all pa-
tients who received at least one dose of study drug,
according to the intention-to-treat principle. Pa-
tients with values missing at week 72 were classi-
fied as having no response.
 
characteristics of the patients
 
Of the 552 patients who underwent randomiza-
tion, 537 were included in the analyses. Five pa-
tients randomly assigned to receive peginterferon
alfa-2a monotherapy, seven assigned to peginter-
feron alfa-2a plus lamivudine, and three assigned
to lamivudine monotherapy were excluded from
analyses — six did not receive study medication,
and all nine patients from a single center were ex-
results
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at UNIVERSITY OF HONG KONG on January 29, 2007 . 
 n engl j med 
 
351;12
 
www.nejm.org september 
 
16, 2004
 
peginterferon alfa-2
 
a
 
 in hb
 
e
 
a
 
g
 
-negative chronic hepatitis b
 
1209
 
cluded owing to irregularities in study conduct. Of
the 537 patients included in the analyses, 26 receiv-
ing lamivudine, 17 receiving peginterferon alfa-2a
plus lamivudine, and 12 receiving peginterferon
alfa-2a monotherapy either did not complete treat-
ment or did not enter or complete follow-up. Base-
line demographic and other characteristics were
similar among the three treatment groups (Table 1).
 
biochemical response
 
At the end of treatment (week 48), the proportion
of patients with normalized alanine aminotrans-
ferase levels was highest with lamivudine mono-
therapy (Table 2). After 24 weeks of follow-up (week
72), the percentage of patients with normalized ala-
nine aminotransferase levels was significantly high-
er with peginterferon alfa-2a monotherapy (59 per-
cent) and peginterferon alfa-2a plus lamivudine (60
percent) than with lamivudine monotherapy (44
percent; P=0.004 and P=0.003, respectively) (Ta-
ble 2 and Fig. 1A). The patterns of alanine amino-
transferase levels throughout the study are shown in
Figure 2A.
During therapy, marked elevations in alanine
aminotransferase (more than 10 times the upper
limit of the normal range, or more than 300 IU per
liter) were observed in a significantly higher per-
centage of patients receiving peginterferon alfa-2a
 
* Race was generally assigned by the investigator but in rare instances was clarified with the patient. 
† The upper limit of the normal range is 30 IU per liter.
 
‡ The presence or absence of bridging fibrosis and cirrhosis was assessed by local pathologists.
 
Table 1. Baseline Characteristics of the Patients.
Characteristic
Peginterferon 
Alfa-2a plus Placebo
(N=177)
Peginterferon 
Alfa-2a plus Lamivudine
(N =179)
Lamivudine
(N=181)
 
Male sex — no. (%) 151 (85) 147 (82) 156 (86)
Race — no. (%)*
White 66 (37) 65 (36) 69 (38)
Asian 107 (60) 111 (62) 111 (61)
Black 3 (2) 2 (1) 0
Other 1 (1) 1 (1) 1 (1)
Age — yr
Mean ±SD 40±11.7 41±10.8 40±11.1
Median 41 40 40
Range 18–71 18–70 18–66
Weight — kg
Mean ±SD 71±12.5 70±13.0 71±12.1
Median 70 68 70.5
Range 47–119 41–114 48–109
Alanine aminotransferase — IU/liter†
Mean ±SD 94.4±85.9 90.8±76.2 105.7±128.2
Median 61.5 64.2 71.6
Range 10.2–507.8 11.3–513.8 9.8–1050.9
HBV DNA — log copies/ml
Mean ±SD 7.14±1.84 7.35±2.00 7.24±1.78
Median 6.99 7.19 6.97
Range 2.3–13.1 2.7–16.9 2.8–13.0
Bridging fibrosis or cirrhosis
 
 
 
—
 
 
 
no. (%)‡ 54 (31) 40 (22) 53 (29)
Prior use of lamivudine — no. (%) 7 (4) 15 (8) 9 (5)
Prior use of interferon alfa — no. (%) 11 (6) 18 (10) 14 (8)
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monotherapy (12 percent) than peginterferon alfa-
2a plus lamivudine (4 percent) or lamivudine mono-
therapy (6 percent; P=0.007 and P=0.038, respec-
tively). In contrast, the percentage of patients with
marked elevations in alanine aminotransferase lev-
els after therapy was significantly higher with la-
mivudine monotherapy (14 percent) or peginterfer-
on alfa-2a plus lamivudine (15 percent) than with
peginterferon alfa-2a monotherapy (7 percent; P=
0.03 and P=0.02, respectively). There was a sig-
nificant association between a marked elevation
in alanine aminotransferase during therapy and
normalization of alanine aminotransferase levels
at week 72 (P=0.01).
 
virologic response
 
At week 48, the percentage of patients with HBV
DNA levels below 20,000 copies per milliliter was
highest with the combination regimen (Table 2).
At week 72, suppression of HBV DNA levels to be-
low 20,000 copies per milliliter occurred in a sig-
nificantly higher percentage of patients receiving
peginterferon alfa-2a monotherapy (43 percent) or
peginterferon alfa-2a plus lamivudine (44 percent)
than lamivudine monotherapy (29 percent; P=0.007
and P=0.003, respectively) (Table 2 and Fig. 1B).
Rates of suppression of HBV DNA to below 400
copies per milliliter at week 72 were 19 percent with
peginterferon alfa-2a monotherapy, 20 percent with
peginterferon alfa-2a plus lamivudine, and 7 per-
cent with lamivudine alone (P<0.001 for both com-
parisons with lamivudine alone).
After 48 weeks, the extent of suppression of
HBV DNA from baseline was greatest with peginter-
feron alfa-2a plus lamivudine (Table 2); the extent
of HBV DNA suppression was similar with peginter-
 
Table 2. Rates of Biochemical, Virologic, and Histologic Response.*
Response End of Treatment (Week 48) End of Follow-up (Week 72)
 
Peginterferon 
Alfa-2a plus 
Placebo
(N=177)
Peginterferon 
Alfa-2a plus 
Lamivudine 
(N=179)
Lamivudine
(N=181)
Peginterferon 
Alfa-2a plus 
Placebo
(N=177)
Peginterferon 
Alfa-2a plus 
Lamivudine
(N=179)
Lamivudine
(N=181)
 
Biochemical response
 
Normalization of alanine 
aminotransferase†
No. of patients — % 67 (38) 87 (49) 132 (73) 105 (59) 107 (60) 80 (44)
95% CI — % 30.7 to 45.4 41.1 to 56.2 65.8 to 79.3 51.7 to 66.6 52.2 to 67.0 36.8 to 51.8
P value 0.004 0.003
Odds ratio — 95% CI‡ 1.9 (1.2 to 2.8) 1.9 (1.2 to 2.9)
 
Virologic response
 
HBV DNA <20,000 copies/ml§
No. of patients — % 144 (81) 164 (92) 154 (85) 76 (43) 79 (44) 53 (29)
95% CI — % 74.8 to 86.8 86.6 to 95.2 79.0 to 89.9 35.5 to 50.6 36.7 to 51.7 22.8 to 36.5
P value 0.007 0.003
Odds ratio — 95% CI‡ 1.8 (1.2 to 2.9) 1.9 (1.2 to 3.0)
HBV DNA <400 copies/ml
No. of patients — % 112 (63) 156 (87) 133 (73) 34 (19) 35 (20) 12 (7)
95% CI — % 55.7 to 70.4 81.3 to 91.7 66.4 to 79.8 13.7 to 25.8 14.0 to 26.1 3.5 to 11.3
P value <0.001 <0.001
Change in HBV DNA
Total no. of patients 166 165 174 165 170 154
Mean log copies/ml ¡4.1 ¡5.0 ¡4.2 ¡2.3 ¡2.4 ¡1.6
95% CI — log copies/ml ¡3.8 to ¡4.5 ¡4.7 to ¡5.3 ¡3.9 to ¡4.5 ¡1.9 to ¡2.7 ¡1.9 to ¡2.8 ¡1.2 to ¡2.0
 
Combined response
 
Normalization of alanine 
aminotransferase and HBV 
DNA <20,000 copies/ml
No. of patients — % 63 (36) 87 (49) 125 (69) 63 (36) 68 (38) 42 (23)
95% CI — % 28.6 to 43.1 41.1 to 56.2 61.8 to 75.7 28.6 to 43.1 30.9 to 45.5 17.3 to 30.0
P value 0.011 0.002
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feron alfa-2a monotherapy and lamivudine mono-
therapy. The patterns of HBV DNA levels through-
out the study are shown in Figure 2B.
 
hb
 
s
 
a
 
g
 
 response
 
At week 72, HBsAg loss occurred in seven pa-
tients receiving peginterferon alfa-2a monothera-
py (five Asian and two white patients) and in five
receiving peginterferon alfa-2a plus lamivudine
(four and one, respectively). HBsAg seroconver-
sion (defined by the loss of HBsAg and the pres-
ence of anti-HBs antibody) occurred in five pa-
tients receiving peginterferon alfa-2a monotherapy
and three receiving the combination regimen. At
week 72, HBsAg loss or seroconversion was not
identified in any patients receiving lamivudine
monotherapy. Differences in HBsAg loss and se-
roconversion between peginterferon alfa-2a mono-
therapy and lamivudine monotherapy were signif-
icant (P=0.007 and P=0.029, respectively, by Fisher’s
exact test).
 
histologic response
 
The rate of histologic response was similar among
the three treatment groups (Table 2). There was a
significant association between improved histo-
 
* All P values are from the Cochran–Mantel–Haenszel test for the pairwise comparison of each peginterferon alfa-2a group with the lamivu-
dine monotherapy group at week 72. CI denotes confidence interval.
† P=0.003 for the overall test of treatment effect.
‡ Odds ratios are given with 95 percent confidence intervals only for the two primary efficacy outcomes.
§ P=0.005 for the overall test of treatment effect.
¶ Histologic response was defined as a reduction of at least two points in the modified Histologic Activity Index score, as compared with the 
pretreatment score, according to criteria of Ishak et al.
 
23
 
¿ Patients without paired biopsy samples were classified as having no response. P=0.144 for the overall test of treatment effect.
** Patients without paired biopsy samples were excluded. P=0.101 for the overall test of treatment effect.
††Ranked assessments included patients with assessable liver-biopsy specimens at baseline and at week 72. “Improved” and “worse” were de-
 
fined as a reduction of at least two points and an increase of at least two points in the modified Histologic Activity Index score, respectively.
 
Table 2. (Continued.)
Response End of Treatment (Week 48) End of Follow-up (Week 72)
 
Peginterferon 
Alfa-2a plus 
Placebo
(N=177)
Peginterferon 
Alfa-2a plus 
Lamivudine 
(N=179)
Lamivudine
(N=181)
Peginterferon 
Alfa-2a plus 
Placebo
(N=177)
Peginterferon 
Alfa-2a plus 
Lamivudine
(N=179)
Lamivudine
(N=181)
Normalization of alanine 
aminotransferase and HBV 
DNA <400 copies/ml
No. of patients — % 47 (27) 82 (46) 109 (60) 26 (15) 29 (16) 11 (6)
95% CI — % 20.2 to 33.7 38.4 to 53.4 52.7 to 67.4 9.8 to 20.8 11.1 to 22.4 3.1 to 10.6
P value 0.007 0.003
 
Histologic response¶
 
No. of patients¿ 177 179 181
Improved — no. of patients (%) 85 (48) 68 (38) 72 (40)
95% CI — % 40.5 to 55.6 30.9 to 45.5 32.6 to 47.3
No. of patients with paired biopsy 
samples**
143 143 125
Improved — no. of 
patients (%)
85 (59) 68 (48) 72 (58)
95% CI — % 50.9 to 67.6 39.1 to 56.1 48.4 to 66.4
 
Ranked assessments of 
histologic response††
 
Necroinflammatory activity
Total no. of patients 143 143 125
Improved — no. of patients (%) 79 (55) 66 (46) 57 (46)
Worse — no. of patients (%) 16 (11) 23 (16) 21 (17)
 
Fibrosis
 
Total no. of patients 143 143 125
Improved — no. of patients (%) 21 (15) 18 (13) 22 (18)
Worse — no. of patients (%) 11 (8) 15 (10) 6 (5)
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
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logic activity and either a biochemical or virologic
response at week 72, regardless of the treatment
group (P<0.001). A histologic response occurred
in 151 of 292 patients with a biochemical response
(52 percent), as compared with 70 of 245 patients
without a biochemical response (29 percent). A his-
tologic response was seen in 116 of 208 patients
with a virologic response (56 percent), as com-
pared with 105 of 329 patients without a virologic
response (32 percent).
 
resistance
 
At week 48, YMDD mutations were detected in 32
of 179 patients receiving lamivudine monother-
apy (18 percent) and 1 of 173 patients receiving
peginterferon alfa-2a plus lamivudine (1 percent,
P<0.001 by Fisher’s exact test).
 
safety
 
The rate of withdrawal from therapy was low in all
three groups (Table 3). The rates of adverse events
were similar in the peginterferon alfa-2a and com-
bination-therapy groups but were significantly less
frequent in the lamivudine group. The most com-
mon adverse events were those known to occur with
conventional interferon alfa therapy, including py-
rexia, fatigue, myalgia, and headache (Table 3).
Depression was infrequent during the study and
was reported by six patients (3 percent) receiving
peginterferon alfa-2a monotherapy, eight patients
(4 percent) receiving peginterferon alfa-2a plus la-
mivudine, and two patients (1 percent) receiving
lamivudine monotherapy. 
Twenty-six patients had a total of 27 serious
adverse events: 9 (5 percent) patients receiving
peginterferon alfa-2a monotherapy, 12 patients
(7 percent) receiving peginterferon alfa-2a plus
lamivudine, and 5 patients (3 percent) receiving la-
mivudine monotherapy (Table 3). Nine patients had
serious infections; however, the incidence was sim-
ilar in each treatment group (1 to 2 percent). There
were two cases of serious thyroid disorders in the
peginterferon alfa-2a group. All other serious ad-
verse events were single cases in a variety of body
systems. Hepatic decompensation was not report-
ed in any patient during the study period, even
though 27 percent of patients had bridging fibro-
sis or cirrhosis on pretreatment liver biopsy.
Mean neutrophil and platelet counts were re-
duced during treatment with peginterferon alfa-2a
monotherapy and peginterferon alfa-2a plus lamiv-
udine, yet returned to baseline levels shortly after
treatment was stopped. Neutropenia and throm-
bocytopenia were the most common reasons for
dose modification (Table 3).
We found that peginterferon alfa-2a alone or in
combination with lamivudine resulted in higher
rates of sustained response among patients with
HBeAg-negative chronic hepatitis B than did lamiv-
udine monotherapy, as reflected by the normaliza-
discussion
 
Figure 1. Rates of Biochemical Response (Panel A) and Virologic Response 
(Panel B) after 24 Weeks of Follow-up.
 
A biochemical response was defined as the normalization of alanine amino-
transferase levels. A virologic response was defined as an HBV DNA level of 
less than 20,000 copies per milliliter. Differences were assessed by means of 
the Cochran–Mantel–Haenszel test, stratified according to geographic region 
and pretreatment alanine aminotransferase level. The number of patients in 
each group is shown in each bar, and the percentage of patients with a response 
in each group is shown above each bar.
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tion of alanine aminotransferase levels, suppres-
sion of HBV DNA, and the loss or seroconversion
of HBsAg. Previous studies have suggested that
low levels of viremia may be compatible with the
presence of minimally active hepatitis B.
 
12,25,26
 
 In
this study, over 40 percent of patients receiving
peginterferon alfa-2a had HBV DNA levels below
20,000 copies per milliliter after 24 weeks of fol-
low-up. This sustained suppression of HBV DNA
(perhaps in combination with normalized alanine
aminotransferase levels) might reduce the risk of
end-stage liver disease or hepatocellular carcinoma.
Longer follow-up is necessary to clarify the long-
term benefits of peginterferon alfa-2a therapy.
 
Figure 2. Mean Serum Alanine Aminotransferase Levels (Panel A) and HBV DNA Levels (Panel B) during the 72-Week 
Study Period. 
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* Values are based on all randomized patients who received at least one dose of study medication and who underwent 
at least one safety assessment after baseline.
† P<0.001 for the overall test of treatment effect.
‡ P=0.913 for the overall test of treatment effect.
§ Some patients who required a dose modification had both an adverse event and a laboratory abnormality.
¶ A serious adverse event was one that presented a clinically significant hazard or resulted in a contraindication or side 
effect.
¿ Thrombotic thrombocytopenic purpura developed in this patient.
** Patients may have had more than one adverse event. The adverse events listed are those reported by at least 5 percent 
 
of patients in one of the peginterferon alfa-2a groups up to eight weeks after therapy.
 
Table 3. Incidence of Discontinuation of Treatment, Dose Modification, and Adverse Events.* 
Variable
Peginterferon Alfa-2a 
plus Placebo
(N=177)
Peginterferon Alfa-2a 
plus Lamivudine
(N=179)
Lamivudine
(N=181)
 
number of patients (percent)
 
Discontinuation
 
For safety reasons† 13 (7) 7 (4) 0 
For other reasons‡ 2 (1) 3 (2) 4 (2)
 
Dose modification§
 
Total 83 (47) 86 (48) —
Adverse event 13 (7) 23 (13) —
Laboratory abnormality 65 (37) 64 (36) —
Alanine aminotransferase elevation 15 (8) 6 (3) —
Neutropenia 30 (17) 44 (25) —
Thrombocytopenia 34 (19) 22 (12) —
 
Adverse events
 
 ≥1 Reported serious adverse event¶ 9 (5) 12 (7) 5 (3)
Death 1 (1)¿ 0 0 
≥1 Reported adverse event† 155 (88) 155 (87) 86 (48)
Most common adverse events**
Pyrexia 105 (59) 98 (55) 8 (4)
Fatigue 74 (42) 75 (42) 33 (18)
Myalgia 47 (27) 49 (27) 11 (6)
Headache 42 (24) 34 (19) 14 (8)
Decreased appetite 31 (18) 26 (15) 6 (3)
Arthralgia 27 (15) 27 (15) 6 (3)
Alopecia 24 (14) 20 (11) 1 (1)
Diarrhea 20 (11) 10 (6) 5 (3)
Dizziness 15 (8) 12 (7) 8 (4)
Insomnia 15 (8) 15 (8) 5 (3)
Nausea 14 (8) 13 (7) 9 (5)
Irritability 12 (7) 8 (4) 4 (2)
Sore throat 11 (6) 5 (3) 8 (4)
Rigors 10 (6) 5 (3) 0 
Injection-site reaction 10 (6) 21 (12) 0 
Cough 10 (6) 5 (3) 2 (1)
Upper respiratory tract infection 9 (5) 4 (2) 7 (4)
Pruritus 9 (5) 11 (6) 4 (2)
Upper abdominal pain 9 (5) 12 (7) 14 (8)
Back pain 4 (2) 11 (6) 6 (3)
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In patients with HBeAg-positive chronic hepati-
tis B, alanine aminotransferase flares during thera-
py with interferon alfa have been indicated as a
significant predictor of response.
 
27
 
 However, this
association is less clear in patients with HBeAg-
negative chronic hepatitis B. The identification of a
significant association between alanine amino-
transferase flares during treatment and response
in this study indicate that alanine aminotransferase
flares may also be predictive of response in these
patients.
HBsAg loss or seroconversion after therapy is
considered the ultimate therapeutic goal of anti-
HBV therapy, since it is associated with positive
long-term clinical outcomes.
 
6,12,28
 
 In this study,
HBsAg loss was identified in 12 patients receiving
peginterferon alfa-2a alone or in combination with
lamivudine, 8 of whom underwent HBsAg sero-
conversion by the end of 24 weeks of follow-up, as
compared with none receiving lamivudine alone.
This observation concurs with those of previous
studies showing that interferon alfa therapy is as-
sociated with an HBsAg response in patients with
HBeAg-negative chronic hepatitis B.
 
29
 
 However, the
HBsAg response elicited by conventional interfer-
on alfa tends to occur later than that observed with
peginterferon alfa-2a in this study.
 
7,10,28
 
 HBsAg
loss or seroconversion was not reported in several
clinical trials of lamivudine or adefovir in patients
with HBeAg-negative chronic hepatitis B.
 
8,9,15,30
 
These results illustrate the importance of the dual
immunomodulatory and antiviral effects of inter-
feron-based therapies in the treatment of HBeAg-
negative chronic hepatitis B.
No significant differences in efficacy were ob-
served between the peginterferon alfa-2a mono-
therapy and combination groups after 24 weeks
of follow-up. This finding extends those of other
recent studies. For example, Santantonio and co-
workers showed that adding conventional inter-
feron alfa to lamivudine therapy did not increase
response rates in patients with HBeAg-negative
chronic hepatitis B when assessed 24 weeks after
the end of treatment.
 
18
 
 Similarly, recent prelimi-
nary data have suggested that after 24 weeks of fol-
low-up, the combination of peginterferon alfa-2b
and lamivudine is no more effective than peginter-
feron alfa-2b monotherapy in patients with HBeAg-
positive chronic hepatitis B.
 
31
 
Significantly fewer patients receiving combi-
nation therapy than lamivudine monotherapy had
YMDD mutations at the end of treatment. This
difference indicates that a more profound HBV
DNA suppression, as seen during treatment with
peginterferon alfa-2a in combination with lamivu-
dine, may lead to a lower incidence of lamivudine
resistance. This finding concurs with general theo-
ries on the development of antiviral drug resistance
and confirms data reported in other studies of
HBV.
 
32
 
 Longer follow-up of patients in this study
may clarify any additional benefits of combination
therapy in the treatment of chronic hepatitis B.
The tolerability and safety profiles of peginter-
feron alfa-2a alone and in combination with lamiv-
udine were satisfactory, and there were no unex-
pected adverse effects. Moreover, the addition of
lamivudine did not substantially alter the safety
profile of peginterferon alfa-2a. The safety profile
of peginterferon alfa-2a also compares favorably
with the profiles described in previous studies of
conventional interferon alfa in patients with HBeAg-
negative chronic hepatitis B.
 
7,33
 
 It is noteworthy
that no patient, including those with bridging fi-
brosis or cirrhosis, had hepatic decompensation
during either treatment or follow-up.
The incidence of depression with peginterferon
alfa-2a in this study (3 to 4 percent) was lower than
previously observed among patients with chronic
hepatitis C (16 to 20 percent).
 
21,34
 
 This finding
concurs with previous data showing that the rate of
depression is lower among patients with chronic
hepatitis B than among patients with chronic hep-
atitis C, both at baseline and during interferon alfa
therapy.
 
35
 
 The reasons for this remain unclear;
however, virus-specific factors (e.g., HCV infection
of the central nervous system) and host-suscepti-
bility factors (e.g., the patient population and the
presence of preexisting psychiatric disorders) may
influence the rates of depression.
 
35,36
 
The results of this large, multinational study
demonstrate that peginterferon alfa-2a offers sig-
nificantly improved efficacy over lamivudine in the
treatment of HBeAg-negative chronic hepatitis B.
The ability of this agent to improve and sustain bio-
chemical, virologic, and HBsAg response rates con-
stitutes a therapeutic advance over current treat-
ments, which are associated with poor rates of
sustained response after the cessation of therapy.
Our data demonstrate the possibility of achieving
HBsAg loss or seroconversion in patients with
HBeAg-negative chronic hepatitis B with the use of
peginterferon alfa-2a and therefore support the use
of this agent as a first-line therapy for HBeAg-neg-
ative chronic hepatitis B.
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